Enter generative AI, which the pharma industry is adopting at a terrific rate. By ingesting and analysing vast biological ...

Biopharma enters 2026 amid continuing scientific progress and accelerating deal activity, yet its business model is under pressure across every facet of the value chain. Investors are taking note: ...

Traditionally, pharmaceutical companies’ interactions with healthcare professionals (HCPs) have been highly personalized — primarily via face-to-face, in-office visits. Recently, however, this model ...

It happens with regularity during citizen open-mike sessions at FDA drug advisory committee hearings. A queue of “patients” materializes out of nowhere to testify, often in tears, about the crucial ...

Royalty Pharma purchases royalties on pharmaceutical products. Diversification provides some protection for investors and the company has invested in high quality assets. Investors face risks ...

On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his ...

Merck CEO Kenneth Frazier said last week that he wants to publicly dissociate innovative pharmaceutical companies like Merck from Turing Pharmaceuticals, the drugmaker criticized for raising the price ...

Influenza Artificial Intelligence model build completedCytoReason analysis of human challenge trial data on track to deliver outputs in Q2 2023 LONDON, UK / ACCESSWIRE / November 29, 2022 / Poolbeg ...

Just when the appetite for European biotech was showing signs of a healthy recovery from the 2001 venture fallout, along comes a recession. But with LP appetite for the buyout market at an all-time ...

PHILADELPHIA--(BUSINESS WIRE)--Big Pharma's dependence on traditional executive compensation plans threatens to work in opposition to the very "medicine" of innovation that could restore the sector's ...